Research programme: 212-Pb immunoconjugates - AREVA Med/RocheAlternative Names: 212-Pb radioimmunotherapy - AREVA Med/Roche; Alpha radioimmunotherapies - AREVA Med/Roche; Lead-212 radioimmunotherapy - AREVA Med/Roche
Latest Information Update: 11 Sep 2013
At a glance
- Originator AREVA Med; Roche
- Class Drug conjugates; Immunotoxins; Monoclonal antibodies; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 27 Jul 2012 Early research in Cancer in Switzerland (unspecified route)